"Advances in Renal Cancer" Journalists' Award 2011 announced Bayer HealthCare and Kidney Cancer Association (KCA) honor medical reporting about renal cancer

Leverkusen, July 2010 - Renal cell carcinoma is one of the most common cancers worldwide. However, there still is a lack of awareness of the disease. Bayer HealthCare and the Kidney Cancer Association (KCA) have therefore announced the European "Advances in Renal Cancer" Journalists’ Award 2011. For the third time, the prize honors journalistic work, in which journalists cover the issue of renal cancer in a critical, but yet objective manner. It is endowed with the sum of Euro 7,500 and awarded to reports which have been published in print media, radio, television, or film. "Malignant tumors in kidney cells are one of the most insidious types of cancer worldwide. They are often only diagnosed at a late stage and have a significant unmet medical need", says Helmut Schäfers, Head of Corporate Communications Europe, Bayer HealthCare, Leverkusen, Germany. "By announcing this award together with specialists in this field, we want to stimulate journalists to report on the disease and publish more information about renal carcinoma and current medical developments." Carrie Konosky, Director of Development &Public Affairs, Kidney Cancer Association, USA, explains: "Our objective is to raise awareness of the symptoms and risk factors of renal cancer and inform the public about new, diagnostic therapy options. That is why the media are an important partner for us." Journalists may submit their applications by March 1, 2011, to th...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

This review focuses on what is the biological basis of esophageal cancer for immunotherapy, how to screen out the patients who can benefit from immunotherapy, and whether the toxic side effects of immunotherapy are manageable. AbstractConsidering the benefits of immunotherapy in advanced melanoma, non –small cell lung cancer, renal cell carcinoma, bladder cancers, and refractory Hodgkin lymphoma, we begin to consider whether immunotherapy is effective for esophageal cancer, which is extremely malignant and has a poor prognosis. There are a large number of clinical trials to study the applicatio n of immunotherapy suc...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: REVIEW Source Type: research
We describe common side effects of this treatment, and advise how they are best prevented and managed.
Source: European Urology - Category: Urology & Nephrology Source Type: research
ConclusionRF ablation, cryoablation, and MW ablation are equivalent at 2 years for treatment of T1a RCC for therapeutic outcome, stability of renal function, and low adverse event rate.
Source: Journal of Vascular and Interventional Radiology - Category: Radiology Source Type: research
FRIDAY, June 21, 2019 -- Prospective validation of existing renal cell carcinoma (RCC) prediction models demonstrates a decrease in their predictive ability, according to a study published online June 19 in the Journal of Clinical Oncology. Andres...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
ConclusionsTo the best of our knowledge, renal malignancy presenting as syndrome of inappropriate antidiuretic hormone secretion and Leser –Trélat concurrently is rare. The causes of hyponatremia in the elderly, approach to investigation, and value as a poor prognostic marker in malignancy are highlighted. We also discuss Leser–Trélat syndrome, its pathophysiology, and its possible implications on clinical practice.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
(University of Pennsylvania School of Medicine) Many elderly patients with metastatic renal cell carcinoma (RCC) -- who are often underrepresented in clinical trials to treat the kidney cancer -- are seeing overall survival benefits from treatment with targeted therapies, according to a new study published in JAMA Network Open.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
AbstractRenal cell carcinoma (RCC) is one of the most lethal urologic malignancies. Its incidence continues to rise worldwide with a rate of 2% per year. Approximately, one-third of the RCC patients are diagnosed at advanced stages due to the asymptomatic nature of its early stages. This represents a great hurdle, since RCC is largely chemoresistant/radioresistant, and targeted therapy of mRCC still has limited efficacy. The 5-year survival rate of metastatic RCC (mRCC) is only around 10%. Adoptive cell transfer (ACT), a particular form of cell-based anticancer immunotherapy, is a promising approach in the treatment of mRC...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
AbstractTumor-associated macrophages have been well-characterized in solid malignancies, including renal cell carcinoma and generally correlate with poor prognosis. However, the molecular mechanisms which govern intratumoral macrophage behavior and patient outcome are unclear. Here, we investigated whether alterations in macrophage expression of the transcriptional regulator for myeloid commitment and function, interferon regulatory factor-8 (IRF8), could predict survival of clear cell renal cell carcinoma patients. Transcriptional analysis of publicly available data revealed elevated IRF8 expression was associated with pr...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
We report surgical safety from a randomised comparison of CN before or after sunitinib. In-hospital mortality, 30-d readmission rate, and intraoperative and 30-d postoperative AEs according to Common Terminology Criteria for Adverse Events version 4 and Clavien-Dindo (CD) were analysed. Patients were randomised 1:1 to immediate CN followed by sunitinib versus sunitinib followed by deferred CN 24 h after the last dose of sunitinib. None of the tumours in the deferred arm became unresectable, and only two patients had a sunitinib-related delay of CN of>2 wk. AEs related to surgery (all grades) in the immediate a...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Genitourinary Cancer Commentaries Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Health | Health Management | Kidney Cancer | Nutrition | Pharmaceuticals | Renal Cell Carcinoma | Urology & Nephrology | Websites | Women